Pembrolizumab Trial for Metastatic Head & Neck Cancers Completes Primary…

A Phase 3 clinical trial (NCT04747054) investigating pembrolizumab in combination with radiotherapy for newly diagnosed metastatic head and neck cancers completed its primary endpoint period on 2025-10-01. The study, titled "Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers," is evaluating the efficacy of this treatment approach.

Background

Pembrolizumab, also known as Keytruda, is an established immunotherapy drug. This trial focuses on its use in Squamous Cell Carcinoma of Head and Neck, a type of cancer that often presents significant treatment challenges, particularly in its metastatic form. The study combines pembrolizumab with radiotherapy, a common treatment modality for head and neck cancers.

Trial design

The "Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers" (NCT04747054) is a Phase 3 clinical trial. It enrolled 102 participants diagnosed with Squamous Cell Carcinoma of Head and Neck. The trial investigates interventions involving pembrolizumab and chemotherapy, aiming to assess their efficacy in this patient population.

What this means

The completion of the primary endpoint period for this Phase 3 trial signifies a critical milestone in the study of pembrolizumab for metastatic head and neck cancers. This event indicates that all necessary data for the primary outcome measure have been collected, and the trial is now proceeding to data analysis and reporting. The results, once available, will provide important insights into the potential role of pembrolizumab in combination with radiotherapy for this challenging cancer type.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04747054, titled "Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers," was posted on 2025-10-01 on clinicaltrials.gov.